Table 1 Patient characteristics of all 155 included patients
Characteristics | FL group (N = 77) | RT group (N = 78) | Total (N = 155) | ||
|---|---|---|---|---|---|
NT group (N = 35) | NT + FL group (N = 23) | FLA group (N = 19) | |||
Age (years), Median (range) | 58(45–71) | 59(43–77) | 56(36–74) | 58(32–73) | 58(32–77) |
Tumor location, n (%) | |||||
Ovary | 35(100) | 23(100) | 19(100) | 77(98.7) | 154(99.4) |
Fallopian tube | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
Primary peritoneum | 0(0) | 0(0) | 0(0) | 1(1.3) | 1(0.6) |
Histology, n(%) | |||||
Serous | 35(100) | 21(91.4) | 18(94.7) | 72(92.3) | 146(94.2) |
Clear cell | 0(0) | 1(4.3) | 0(0) | 3(3.8) | 4(2.6) |
Mucinous | 0(0) | 0(0) | 1(5.3) | 2(2.6) | 3(1.9) |
Others | 0(0) | 1(4.3) | 0(0) | 1(1.3) | 2(1.3) |
Tumor grade, n(%) | |||||
High | 34(97.1) | 23(100) | 18(94.7) | 73(93.6) | 148(95.5) |
Low | 1(2.9) | 0(0) | 1(5.3) | 5(6.4) | 7(4.5) |
FIGO stage, n(%) | |||||
I | 0(0) | 0(0) | 0(0) | 2(2.6) | 2(1.3) |
II | 0(0) | 0(0) | 1(5.3) | 7(9.0) | 8(5.2) |
III | 19(54.3) | 14(60.9) | 12(63.2) | 46(59.0) | 91(58.7) |
IV | 13(37.1) | 9(39.1) | 6(31.5) | 22(28.2) | 50(32.3) |
Unknown | 3(8.6) | 0(0) | 0(0) | 1(1.2) | 4(2.5) |
Administration route, n(%) | |||||
Intravenous | 30(85.7) | 22(95.7) | 19(100) | 61(78.2) | 132(85.2) |
Intraperitoneal | 1(2.9) | 0(0) | 0(0) | 8(10.3) | 9(5.8) |
Intrathoracic | 1(2.9) | 0(0) | 0(0) | 2(2.6) | 3(1.9) |
≥ 2 routes of administration | 3(8.5) | 1(4.3) | 0(0) | 7(8.9) | 11(7.1) |
Dosage (mg/kg), n(%) | |||||
15 | 7(20) | 12(52.2) | 8(42.1) | 16(20.5) | 43(27.7) |
7.5 | 25(71.4) | 11(47.8) | 11(57.9) | 53(67.9) | 100(64.5) |
5 | 3(8.6) | 0(0) | 0(0) | 9(11.6) | 12(7.8) |
Germline BRCA status, n(%) | |||||
BRCA1 mutation | 5(14.3) | 1(4.3) | 1(5.3) | 10(12.8) | 17(11) |
BRCA2 mutation | 1(2.8) | 1(4.3) | 3(15.8) | 3(3.8) | 8(5.2) |
BRCA wild-type | 21(60) | 20(87.1) | 14(73.6) | 52(66.7) | 107(69) |
Unknown | 8(22.9) | 1(4.3) | 1(5.3) | 13(16.7) | 23(14.8) |